For patients with type 2 diabetes and DN, follow-up time was divided into time spent in the following clinical states: DN, CVD, and ESRD in chronologic.

Slides:

Advertisements

Similar presentations

Skip Counting Counting by 2, 5, and 10.

Advertisements

Notes Over 12.5 Probability of Independent Events 1. You are playing a game with 2 numbered cubes. Find the probability of rolling a sum of 8 on the first.

FRACTIONS & SHAPES BY:. How many of these are colored red? * out of *.

Improved prognosis of diabetic nephropathy in type 1 diabetes

Figure 1. Serum creatinine trend in the patient

Skip Counting Counting by 2, 5, and 10.

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Name: _______________________________

Skip Counting Counting by 2, 5, and 10.

Can I color yellow?. Can I color yellow?

What Color is it?.

Obesity and type 2 diabetes forecasts.

Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.

Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

Scatterplot showing the association between baseline weight and weight change at 1 year, relative to baseline for each treatment group. Scatterplot showing.

Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and.

Improved prognosis of diabetic nephropathy in type 1 diabetes

Color Box Button - Gray Type : object Type : object Type : object

Decreased P-IR and total FOXO1 levels in an HFS diet.

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

Trends in prevalence of diabetes in middle-aged women grouped according to BMI at the first survey of the ALSWH. ▪, healthy (n = 5,252); ♦, overweight.

Mean (95% CI) fasting s-glucose at baseline and 6-month, 12-month, and 24-month follow-up, overall and by sex (A), and by baseline age (B), education (C),

Predicted percentage of home discharge by diabetes group adjusting for all variables listed in the age-centered logistic regression model with examination.

Age-adjusted OR (A) and multivariate-adjusted OR (B) and 95% CI for the presence of retinopathy and albuminuria by quintiles of WBC count in 3,776 patients.

The incidence of insulin-treated type 1 diabetes in the first 35 years of life. The incidence of insulin-treated type 1 diabetes in the first 35 years.

Causal diagram showing assumed associations between baseline smoking status, ESRD, and baseline characteristics in the Study of Heart and Renal Protection.

Prevalence of clinically significant microvascular (green) and clinically significant macrovascular (yellow) disease alone and combined microvascular and.

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

Forefoot peak plantar pressure in diabetic patients without and with mild, moderate, and severe peripheral neuropathy. *Severe and moderate neuropathy.

Pooled risk with 95% CI of ACM (A) and CVD risk (B) for the highest vs

A: Representative hydrophilic interaction liquid chromatography–ultra performance liquid chromatographic profile of N-glycans released from total plasma.

Kaplan-Meier estimation of diabetes-related survival curves in patients grouped according to increased 24-h proteinuria (A), the presence of preexisting.

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

Two-year changes in albumin-to-creatinine ratio across microalbuminuria at baseline. Two-year changes in albumin-to-creatinine ratio across microalbuminuria.

Association of ISI with all-cause mortality as modeled by cubic spline, adjusted for age, sex, race, and study site, among 3,138 participants in the CHS.

Baseline predictors of acute complication of diabetes among immigrants with language barriers (N = 87,707). *Adjustment for all variables listed, as well.

Baseline predictors for risk of cardiovascular events or all-cause mortality among immigrants with language barriers (N = 87,707). *Adjustment for all.

Mean decline in grip strength with aging is shown for participants categorized by baseline quartile of 2 h glucose (2HG). Mean decline in grip strength.

Trends in the use of head CT and advanced imaging in patients treated with IV thrombolysis from 2008 to Trends in the use of head CT and advanced.

Partial pedigrees for novel INS mutations identified in probands with MODY and young type 2 diabetes. Partial pedigrees for novel INS mutations identified.

Waveform analysis at the popliteal artery in 176 diabetic patients with normal ABI (non-PAD). Waveform analysis at the popliteal artery in 176 diabetic.

Effect of empagliflozin on efficacy parameters at week 18.

Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

HRs (and 95% CIs) for incident type 2 diabetes for a doubling of total flavonoid (A) and lignan (B) intakes across countries in the InterAct study. HRs.

Trends in mortality by age-groups and select CVDs among adults with diabetes. Trends in mortality by age-groups and select CVDs among adults with diabetes.

Pooled analysis of association between (nonexclusive) breast-feeding and childhood-onset type 1 diabetes in studies investigating ∼2 weeks (nonexclusive)

Percent binding of cross-reactive antibodies from cross-over studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

Percent binding of cross-reactive antibodies from parallel studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

Progression to micro- or macroalbuminuria.

Relationship between time from diagnosis of type 2 diabetes to renal biopsy and the proportion of biopsies with any diabetic nephropathy (DN) and any non-diabetic.

Maria R. Costanzo et al. JCHF 2016;4:

One-year cumulative incidence rates of adverse clinical outcomes in 9,428 outpatients with CHF stratified by diabetes status at baseline. One-year cumulative.

A: Typical course of a normal sympathetic vasomotor response as recorded by continuous wave Doppler sonography. A: Typical course of a normal sympathetic.

A: Probability of retinopathy-free survival.

Mean HbA1c (%) and estimated marginal mean SH rate (per 100 patient-years) adjusted for sex, age-group at diagnosis, and diabetes duration, by time period,

Correlation between urinary albumin excretion rate and expression of platelet surface markers, active GPIIb/IIIa, and P-selectin. Correlation between urinary.

Incidences of transitions between glycemic states by 25-OHD level.

A1C at baseline, 16 weeks, and 32 weeks according to study group in all participants (A), adult participants (B), and adolescent participants (C) who returned.

Effects of PCSK7 rs genotype and CHO diets on changes and reversion in fasting insulin levels and HOMA-IR during the 2-year intervention in white.

Sodium consumption (mg/day) at baseline by demographic characteristics in a cohort of self-referred patients with type 2 diabetes. Sodium consumption (mg/day)

Kaplan-Meier survival (renal event-free) curves during follow-up by tertiles of plasma copeptin. Kaplan-Meier survival (renal event-free) curves during.

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension.

Typical images of a patient without brain metastases derived via automatic segmentation software. Typical images of a patient without brain metastases.

A: Executive function performance assessed by D-KEFS Trail Making task (Number-Letter Switching) and depicted according to presence or absence of CVD in.

Survival, subsequent therapies, and response.

Risk of mortality in patients with diabetes and ESRD

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Adjusted HRs for death from any cause and death from specific causes among patients with type 1 diabetes. Adjusted HRs for death from any cause and death.

Presentation transcript:

For patients with type 2 diabetes and DN, follow-up time was divided into time spent in the following clinical states: DN, CVD, and ESRD in chronologic order as shown in this multistate model with age, diabetes duration, and DN duration as underlying time scales. For patients with type 2 diabetes and DN, follow-up time was divided into time spent in the following clinical states: DN, CVD, and ESRD in chronologic order as shown in this multistate model with age, diabetes duration, and DN duration as underlying time scales. Numbers in boxes represent the sum of person-years in the state; numbers on the arrows are number of patients that change state with rates in % per year in the parentheses. Patients with CVD at baseline started in the CVD state (blue box); otherwise, all patients started in the DN state (green box). Green, DN only; blue, CVD; red, ESRD including doubling of p-creatinine; yellow, ESRD and CVD. Framed boxes with lighter colors represent those who died in the above-mentioned states. Gudbjörg Andrésdóttir et al. Dia Care 2014;37:1660-1667 ©2014 by American Diabetes Association